Movano (NASDAQ:MOVE – Get Free Report) and Fulgent Genetics (NASDAQ:FLGT – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.
Insider & Institutional Ownership
16.6% of Movano shares are held by institutional investors. Comparatively, 48.1% of Fulgent Genetics shares are held by institutional investors. 10.4% of Movano shares are held by company insiders. Comparatively, 31.8% of Fulgent Genetics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Analyst Ratings
This is a summary of current ratings and target prices for Movano and Fulgent Genetics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Movano | 1 | 0 | 0 | 0 | 1.00 |
| Fulgent Genetics | 1 | 1 | 2 | 0 | 2.25 |
Profitability
This table compares Movano and Fulgent Genetics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Movano | -3,409.60% | -647.91% | -225.03% |
| Fulgent Genetics | -13.62% | -2.55% | -2.36% |
Volatility and Risk
Movano has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500. Comparatively, Fulgent Genetics has a beta of 0.65, indicating that its stock price is 35% less volatile than the S&P 500.
Valuation & Earnings
This table compares Movano and Fulgent Genetics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Movano | $1.01 million | 6.51 | -$23.73 million | ($10.83) | -0.73 |
| Fulgent Genetics | $283.47 million | 2.95 | -$42.71 million | ($1.39) | -19.45 |
Movano has higher earnings, but lower revenue than Fulgent Genetics. Fulgent Genetics is trading at a lower price-to-earnings ratio than Movano, indicating that it is currently the more affordable of the two stocks.
Summary
Fulgent Genetics beats Movano on 10 of the 14 factors compared between the two stocks.
About Movano
Movano Inc. engages in developing a platform to deliver healthcare solutions at the intersection of medical and consumer devices. The company is involved in the development of Evie Ring, which is a wearable designed specifically for women that combines health and wellness metrics comprises resting heart rate, heart rate variability (HRV), blood oxygen saturation (SpO2), respiration rate, skin temperature variability, period and ovulation tracking, and menstrual symptom tracking, as well as activity profile, including steps, active minutes and calories burned, sleep stages and duration, and mood tracking. It develops System-on-a-Chip (SoC) for blood pressure or continuous glucose monitoring (CGM) systems. The company was formerly known as Maestro Sensors Inc. and changed its name to Movano Inc. in August 2018. Movano Inc. was incorporated in 2018 and is based in Pleasanton, California.
About Fulgent Genetics
Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.
Receive News & Ratings for Movano Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Movano and related companies with MarketBeat.com's FREE daily email newsletter.
